Phuturdex › Diseases › Cardiotoxicity
Drugs in development · updated 30 October 2026
Cardiotoxicity: drugs in development
As of 30 October 2026 there are 11 active clinical trials (recruiting or ongoing, phases I–III) on 21 drugs for cardiotoxicity. 5 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Empaglifloz | III | 1 | NCT07852546 |
| Atrovastain | I–II | 1 | NCT06684509 |
| Nicorandil Oral Tablet | II | 1 | NCT07897409 |
| Sulforaphane | I–II | 1 | NCT03934905 |
| 68Ga-Galmydar | I | 1 | NCT07838649 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| DoxorubicinAdriamycin, Doxorubincin | III | 4 | NCT07852546 |
| CyclophosphamideCyclophosphamid, Cytoxan | III | 2 | NCT06220032 |
| DexrazoxaneTotect®, Zinecard® | III | 2 | NCT06220032 |
| RituximabRuxience, Rituxan | III | 2 | NCT06220032 |
| VincristineVincristin, Oncovin [vincristine] | III | 2 | NCT06220032 |
| CarvedilolCoreg Cr®, Coreg® | III | 1 | NCT03418961 |
| EmpagliflozinJardiance | III | 1 | NCT05271162 |
| LenalidomideRevlimid, lenalinomide | III | 1 | NCT06220032 |
| PegfilgrastimArmlupeg®, Stimufend® | III | 1 | NCT06220032 |
| PrednisolonePrednisolon, Prenisolone | III | 1 | NCT06220032 |
| AtorvastatinLipitor, Atorvaliq® | II | 1 | NCT05559164 |
| Pegylated liposomal doxorubicinLiposomal Doxorubicin, DOXIL | II | 1 | NCT07654426 |
| Polatuzumab VedotinPolivy® | II | 1 | NCT07654426 |
| PrednisonePredinisone, Cortancyl | II | 1 | NCT07654426 |
| SotagliflozinInpefa®, Zynquista® | II | 1 | NCT07572175 |
Sorted by most advanced phase and number of active trials. Showing 15 of 16 drugs.
All 21 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Broader categories
- Radiation Injuries 13 drugs
- Wounds and Injuries 25 drugs
- Heart disease 17 drugs
- Adverse drug reaction 11 drugs
- Cardiovascular disease 71 drugs
- Neoplasm 671 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D066126 “Cardiotoxicity”.